PDSB News and Press, PDS Biotechnology Corporation From 04/05/23

2023-04-05 06:57:49 ET Summary PDS0101, an innovative immunotherapy, targets HPV-positive cancers, including recurrent or metastatic head and neck cancer with high-risk HPV16 infection. VERSATILE-002 Phase 2 clinical trial demonstrates improved efficacy and a favorable safety prof...

FLORHAM PARK, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced its support for Oral, Head & Neck Cancer Aware...

FLORHAM PARK, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced that it has completed key tech transfer, scale up ...

FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Chief Ex...

2023-03-28 15:03:05 ET PDS Biotechnology Corporation (PDSB) Q4 2022 Results Earnings Conference Call March 28, 2023, 08:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chie...

2023-03-28 07:34:01 ET PDS Biotechnology press release ( NASDAQ: PDSB ): FY GAAP EPS of -$1.43 misses by $0.35 . The Company’s cash balance as of December 31, 2022, was $73.8 million. Based on the Company’s available cash resources and cash flow projectio...

Successful meeting with FDA to discuss registrational pathway for triple combination of PDS0101, PDS0301, and a commercial immune checkpoint inhibitor 100% (9/9) clinical response (>60% tumor shrinkage at mid-point evaluation) in IMMUNOCERV trial for high-risk cervical cancer patients ...

2023-03-27 13:52:22 ET PDS Biotechnology ( NASDAQ: PDSB ) is scheduled to announce Q4 earnings results on Tuesday, March 28th, before market open. The consensus EPS Estimate is -$0.30 and the consensus Revenue Estimate is $0M For further details see: PDS Biotechn...

FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will release financial results ...

FLORHAM PARK, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Chief Ex...